Zealand Pharma Balance Sheet Health
Financial Health criteria checks 3/6
Zealand Pharma has a total shareholder equity of DKK366.4M and total debt of DKK368.5M, which brings its debt-to-equity ratio to 100.6%. Its total assets and total liabilities are DKK1.1B and DKK725.2M respectively.
Key information
100.6%
Debt to equity ratio
kr.368.52m
Debt
Interest coverage ratio | n/a |
Cash | kr.342.58m |
Equity | kr.366.44m |
Total liabilities | kr.725.17m |
Total assets | kr.1.09b |
Recent financial health updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 22ZA's short term assets (DKK833.9M) exceed its short term liabilities (DKK225.9M).
Long Term Liabilities: 22ZA's short term assets (DKK833.9M) exceed its long term liabilities (DKK499.2M).
Debt to Equity History and Analysis
Debt Level: 22ZA's net debt to equity ratio (7.1%) is considered satisfactory.
Reducing Debt: 22ZA's debt to equity ratio has increased from 22.2% to 100.6% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 22ZA has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if 22ZA has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.